Growing community of inventors

Paris, France

Fanny Mochel

Average Co-Inventor Count = 2.59

ph-index = 3

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 102

Fanny MochelRaphael Schiffmann (4 patents)Fanny MochelAlexandra Durr (2 patents)Fanny MochelLawrence Sweetman (2 patents)Fanny MochelSabrina Forni (2 patents)Fanny MochelGiovanni Stevanin (1 patent)Fanny MochelFrédéric Darios (1 patent)Fanny MochelJulien Branchu (1 patent)Fanny MochelMaxime Boutry (1 patent)Fanny MochelAlexandra Dürr (0 patent)Fanny MochelFanny Mochel (7 patents)Raphael SchiffmannRaphael Schiffmann (6 patents)Alexandra DurrAlexandra Durr (2 patents)Lawrence SweetmanLawrence Sweetman (2 patents)Sabrina ForniSabrina Forni (2 patents)Giovanni StevaninGiovanni Stevanin (5 patents)Frédéric DariosFrédéric Darios (1 patent)Julien BranchuJulien Branchu (1 patent)Maxime BoutryMaxime Boutry (1 patent)Alexandra DürrAlexandra Dürr (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Institut National De La Sante Et De La Recherche Medicale (3 from 1,745 patents)

2. Baylor Research Institute (3 from 93 patents)

3. National Institute of Health and Medical Research (2 from 2 patents)

4. Other (1 from 832,912 patents)

5. Centre National De La Recherche Scientifique (1 from 5,094 patents)

6. Sorbonne Université (1 from 240 patents)

7. Assistance Publique - Hopitaux De Paris (Aphp) (1 from 71 patents)

8. Icm-Institut Du Cerveau Et De La Moelle Epiniere (1 from 9 patents)

9. Ecole Pratique Des Hautes Etudes (1 from 5 patents)

10. Inserm (0 patent)


7 patents:

1. 11065238 - Inhibitors of gangliosides metabolism for the treatment of motor neuron diseases

2. 10220014 - Anaplerotic therapy of huntington disease and other polyglutamine diseases

3. 10111848 - Triheptanoin for the treatment of glucose transport 1 deficiency

4. 9750732 - Urinary triaosylceramide (Gb3) as a marker of cardiac disease

5. 9717705 - Anaplerotic therapy of huntington disease and other polyglutamine diseases

6. 9468229 - Triheptanoin for the treatment of glucose transport 1 deficiency

7. 9066939 - Urinary triaosylceramide (GB3) as a marker of cardiac disease

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
1/10/2026
Loading…